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PRevention and tReatMent of Missing data in Real WoRld ReseaRch
Gemmen E
Quintiles, Inc., Rockville, MD, USA
PurPose: The objective of this presentation is to bring awareness to the challenges of 
missing data from study design and analysis perspectives, and to discuss study design 
elements and analysis methods that support meaningful and valid inferences in both 
prospective and retrospective observational research used to generate real-world 
evidence for payers and health technology assessment authorities. DescriPtion: 
Observational studies are increasingly used to study the post approval drug exposed 
population for drug and medical effectiveness and safety assessments. Understanding 
the potential sources of missing data from a study whose design imposes structure on 
data captured from real world clinical practice allows the selection of study design ele-
ments that may help reduce the magnitude of missing data. Given the occurrence of 
missing data, analysis methods that support valid and meaningful conclusions from 
observational research are necessary. This presentation starts with an overview of the 
potential sources of missing data in observational research, including PRO assess-
ments and retrospective clinical data; then focuses on proactive planning of data 
collection and analysis. The types of missing data (missing due to study withdrawal; 
directly reported as missing; non-reported; uninterpretable value; out-of-range value) 
and statistical approaches for handling missing data including examining missing 
data patterns and testing missingness mechanisms, effective and advanced analytic 
methods (imputation, likelihood based and weighted approaches), when these meth-
ods should be applied, and the impact of missing data to the interpretation of study 
findings will be discussed. The concepts and methods will be explained with the use 
of real-world observational study data, including patient registries, electronic medical 
records, patient charts, and claims data.
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sugaMMadex: the Right oPtion foR the efficiency of the oPeRating 
RooM? a Methodology foR cost / Benefit analysis in coMPaRison to 
the Routine choice foR ReveRsal
Ronco GL
Emmonos S.A., Fenegro’, Italy
BAckgrounD: In face to the financial environment in which health facilities cur-
rently are evolving, it is now clear and shared that only through a good organization 
of the surgical event it is possible to achieve significant improvements in quality 
of care. In this way the economic impact becomes inversely proportional because 
the establish oneself of the virtuous circle that leads (or at least should lead) to 
a adequate request of resources that are used in a so much appropriate way to 
obtain the most practical benefit that ultimately produces case-mixes with high 
profitability, a good level of quality perceived as high and expenses pragmatically 
supported by the revenues. endpoints The primary endpoint of this study aims to 
assess, starting from the costs that the information analyzed allow to accurately 
calculate, the increased efficiency achieved by the availability to the anesthesiologist 
of sugammadex rather than its unavailability. Moreover, the secondary endpoint 
aims to formulate organizational scenarios to permit the unlimited use of sugam-
madex rather than have availability of it in a controlled amount for use based on a 
protocol. Furthermore, it tries to identify the surgical specialties in which each of 
the two scenarios can be applied with the highest profit. Methodology The Cost / 
Benefit Analysis (CBA) requires that the clinical indicators obtained be monetized 
by referring to cost and revenue. It is essential retrieve the information from the 
anesthesiology medical records (the prerequisite of validity for inclusion of the 
anesthesiology medical record is the presence of observation of the state of neu-
romuscular blockade by use of objective monitoring tools). Furthermore, it needs 
to retrieve the costs of the activity of the operating theatre from the management 
control system of the hospital. The revenues come from the clinical medical records.
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oBjectives: A recent cluster randomised controlled trial (RCT) conducted in an 
Irish hospital evaluating a structured pharmacist review of medication (SPRM) sup-
ported by computerised decision support software (CDSS) demonstrated positive 
outcomes in terms of reduction of adverse drug reactions (ADR). The aim of this 
study was to examine the cost-effectiveness of pharmacists applying a SPRM in 
conjunction with CDSS to older hospitalised patients compared to usual pharma-
ceutical care. MethoDs: Cost-effectiveness analysis alongside a cluster RCT. The 
trial was conducted in a tertiary hospital in the south of Ireland. The intervention 
arm patients (n= 361) received a multi-factorial intervention consisting of medicines 
reconciliation, deployment of CDSS and generation of pharmaceutical care plan for 
patient. Control arm patients (n= 376) received usual care from the hospital phar-
macy team. Incremental cost-effectiveness was examined in terms of costs to the 
healthcare system and an outcome measure of ADRs during an inpatient hospital 
stay. Uncertainty in the analysis was explored using a cost-effectiveness accept-
ability curve (CEAC). results: On average, the intervention arm was the dominant 
strategy in terms of cost-effectiveness. Compared to standard care (control), the 
intervention was associated with a decrease of € 815 (95% Confidence intervals (CI) 
-3451, 1820) (p = 0.544) in mean healthcare cost and a decrease in the mean number 
of ADR events per patient of -0.064 (95% CI -0.135, 0.008) (p = 0.081). The probability of 
the intervention being cost-effective at respective threshold values of € 0, € 250, € 500, 
for Tiotropium seen in blinded trials. Our examples demonstrate the useful applica-
tion of classical meta-analytic methods to assess heterogeneity across groups of 
trials based on aggregate data of relative treatment effect and its variability.
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oBjectives: This study aims to develop a theoretical scheme to achieve value-
based pricing in consideration of the efficiency with respect to the cost-effective-
ness dominance of a new technology, compared to the best control or the next best 
one. MethoDs: Suppose that a pair of cost and benefit of a new technology, the 
best control and next best one is respectively represented as three points with X(Ex, 
Cx), S(Es, Cs) and S’(Es’, Cs’) on the cost-effectiveness plane, assuming the inequali-
ties Es’ < Es < Ex and Cs’ < Cs < Cx. Let Cx be a variable, while the other parameters 
all constant. Considering geometric relations between the three points, we iden-
tify the areas where point X should be located according to the categories: simple 
dominance, extended dominance and non-dominance, in which we formulate the 
association between the expected cost Cx and the incremental cost-effectiveness 
ratio (ICER) of point X: (Cx - Cs)/(Ex - Es) compared to point S and (Cx - Cs’)/(Ex - Es’) 
to point S’. results: Three ranges for Cx were identified for each of the dominance 
categories, respectively, 1) lower than Cs’, 2 ) between Cs’ and Cm, and 3) greater 
than Cm, where Cm was estimated with the expression of ((Ex - Es’)Cs - (Ex - Es)Cs’)/
(Es - Es’). The expected cost Cx was formulated as a linear function of the ICER: Cx = 
Cs’ + (Ex - Es’)*ICERs’-x in case of dominance, whether simple or extended, and Cx = 
Cs + (Ex - Es)*ICERs-x for non-dominance. Based on the formulae, the maximal cost 
accepted in each category was determined in theory and with examples, taking an 
ICER threshold into account. conclusions: Our approach will provide decision 
makers with a scientific scheme for value-based pricing, and clarify the value position 
in consideration of economic efficiency.
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hta studies foR Medical devices incoRPoRating theiR MoRal ageing
Kamensky V, Rogalewicz V, Fortova B, Simackova J, Kneppo P
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oBjectives: Due to specificities of medical devices (short lifetime, learning curve, 
limited approval process, steady technological development, etc.), it is desirable to 
take account of moral aging in HTA studies focused on devices. However, methods that 
might be used to evaluate innovations that are brought by a new generation of instru-
ments (and consider them in assessments of the older ones) are not well defined 
yet, although they are considered topical by many recent journal and conference 
papers. MethoDs: The paper consists of two parts. First, the history of innovations 
and their incorporation in HTA studies was studied for three typical devices (stents, 
MRI, left ventricular assist device – LVAD) with the focus on the delays in the particu-
lar analyses. Second, based on a literary review, a recommendation was formulated 
for assessment of devices in the case when innovations appear rapidly after each 
other. results: It is shown that older generations of devices are often being assessed 
when substantial innovations are already available, without taking them into con-
sideration. Classic CEA is probably difficult to apply. Two possible approaches were 
selected: MCDA applied on the effect side of the CEA (a modification of the method 
suggested by Rosina et al., Lékař a technika 44(3), 2014, 23-36), and the headroom 
method (Cosh et al., J Commer Biotechnol 13(4), 2007, 263-71). Their application is 
illustrated in the case of LVAD. CONCLUSION: The current methodologies for medi-
cal device assessment do not consider their moral ageing and/or innovations. The 
headroom method and/or MCDA may be a partial solution, as this paper suggests. 
Further more extensive studies are necessary in this direction.
PRM282
clinical Multi-cRiteRia decision assessMent (cMda): a PRoPosal 
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There are plenty of different clinical and economic parameters to consider in order 
to choose the best treatments. RCT and consequent Mixed Treatment Comparison 
(MTC) are based on the assessment of one single criterion, we need to move to a 
transparent and systematic framework enabling decision makers to assess all rel-
evant parameters simultaneously in order to evaluate the best intervention. In order 
to apply the Multiple Criteria Decision Analysis (MCDA) methodology to both clinical 
setting and decision making process we suggest the application of a model of MCDA 
as Clinical Multi-criteria Decision Assessment (CMDA). In this model of CMDA, we 
apply the methodology of MCDA in the context of a single disease, ie to compare 
biologicals in rheumatoid arthritis. Like for the general framework of MCDA, in 
CMDA there is not one predominant criterion; the innovative approach is to consider 
a “clinical consensus” for the selection of all relevant criteria (domains) and related 
parameters for evaluation, and the following attribution of specific weights. This 
means that clinical outcome measured on a specific endpoint (parameters) will 
be weighted according to the importance that a clinical consensus will give to the 
specific domain. This helps guaranty a transparent and objective evaluation. Results 
from both meta-analysis and observational studies are used by a clinical consensus 
after attributing weights to specific domains and related parameters. Decision will 
result from a related comparison of all parameters (i.e. efficacy, safety). The match 
will yield a score (in absolute value) that link each parameter with a specific inter-
vention, and then a final score for each treatment. The higher is the final score; the 
most appropriate is the intervention to treat disease considering all criteria (domain 
and parameters). The results will allow physicians evaluate best clinical treatment 
considering at the same time all relevant criteria.
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other indications 15.23% (n= 1320). Comparing prescribing across the six sites, car-
diovascular indications remained the most common and showed the lowest rela-
tive standard deviation across the six sites (x ̅= 41.38%, SD = ±6.68, RSD = 16.14%). 
Respiratory tract (x   ̅= 9.56%, SD= ±6.24, RSD= 65.27%) and musculoskeletal indica-
tions (x ̅= 3.78%, SD= ±2.35, RSD= 62.17%) showed the greatest variation in prescrib-
ing across the six sites. conclusions: Prescribing for cardiovascular indications 
accounted for the highest percentage of medications at each individual site. It was 
also the most consistent, showing the lowest variation in percentages across all 
six sites. This supports the fact that cardiovascular criteria make up the largest 
section of the STOPP/START criteria. Prescribing for respiratory tract and muscu-
loskeletal indications showed the highest level of variation across the six sites. 
This variation may be indicative of over-prescribing in some sites and under-
prescribing in others.
Pih6
the BuRden of adult PneuMococcal disease in 50+ PoPulation in 
hungaRy
Salfer B, Somfay I, Nagy B
Healthware Consulting Ltd., Budapest, Hungary
oBjectives: The prevalence of pneumonia, meningitis and septicemia cases 
recorded among 50+ Hungarian population has been growing. One of the main 
reasons of the year by year higher occurrences is the ever ageing population, 
where the incidence is higher generating significant incremental resource utiliza-
tion. MethoDs: The study determines whether the probability of morbidity over 
50+ has changed (using general linear model - GLM) and the direct health care cost 
of the three mentioned diseases based on the National Health Insurance Fund 
database. Cases and direct healthcare cost of inpatient, outpatient care, diagnos-
tics and medication were defined with an analysis of the Hungarian population. 
The study that covers the 2005-2013 timeframe in 5 year age-groups does not 
calculates indirect burden. results: The research shows that the age increases 
the probability of disease. Between the age groups 40-49 and 50-54 the probability 
of disease increased by 26% (from GLM model, which is significant) and growing 
in each age-group. The prevalence of analyzed diseases among 50+ Hungarian 
population has increased by 10% between 2005 and 2013 resulting an incremental 
2.34 billion HUF extra direct health care cost expenditure. Approximately 77% 
of this extra amount was used by the 65+ population. Worthy to note that the 
disease specific mortality among 50+ Hungarian population is 1.8 times higher 
in 2013 compared to 2005 and reached 18,954 inhabitants. Because of the disease 
specific death and direct health care cost an approx. 9.3 billion HUF direct health 
care burden was reported in year 2013 among the 50+ population. conclusions: 
The health care attendance of pneumonia, meningitis and septicemia diseases 
effects a huge burden on the health care system that grows year by year. By the 
help of a targeted pneumococcal vaccination program a part of the ever growing 
yearly burden could be avoided.
Pih7
PRevalence and incidence of MalnutRition aMong geRiatRics 
PoPulation in tuRkey
Koksal I1, Gulkan S1, Dogukan MN1, Tezcan ES1, Ozcan O1, Berktas M2
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oBjectives: Malnutrition is a health problem in adulthood period of life. 
Epidemiologic data of malnutrition in adults is limited in Turkey although there 
are several studies focusing on malnutrition in selected populations. This abstract 
aims to report prevalence and incidence of malnutrition in geriatric population in 
Turkey using general health insurance reimbursement database of Social Security 
Institute (SSI). MethoDs: Since 2011, the Turkish general health insurance sys-
tem has covered 98% of total population of Turkey and the only reimbursement 
authority of general health insurance is SSI. Therefore statistics obtained via the 
SSI database are highly representative of the population of Turkey. From SSI data-
base, person ≥ 65 years of age who received first malnutrition diagnosis between 
1 January 2011 and 31 December 2013 were included to analysis. International 
Classification of Disease (ICD)-10 code E40 to E46 were used to define malnutrition. 
Concomitant diseases to malnutrition were out of abstract scope. results: Of 
931,079 unique persons at any age had at least one primary malnutrition diagnosis; 
40,109 adults met selection criteria of this abstract. Annual incidence of malnutri-
tion was 0.367%, 0.419% and 0.464% in 2011, 2012 and 2013, respectively (0.123%, 
0.125% and 0.164% in females and 0.145%, 0.150% and 0.196% in males for same 
time periods). Prevalence of malnutrition was 0.254% and 0.341% in 2011-2012 and 
2012-2013 periods, respectively (0.245% and 0.329% in females and 0.266% and 
0.356% in males for same time periods). conclusions: The study showed the 
prevalence and incidence of malnutrition among geriatric population in Turkey. 
Males are under more risk than females, and both prevalence and incidence of 
malnutrition among geriatric population increase. In conclusion; more efficient 
strategies for diagnosis and treatment of malnutrition in geriatric population of 
Turkey should be developed.
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PRevalence of self-Medication and its Reason aMong PhaRMacy 
students in india: a cRoss-sectional study
Hussain S
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oBjectives: To assess the prevalence of self-medication and its reason among 
Postgraduate Pharmacy students. MethoDs: This cross-sectional study was con-
ducted among Postgraduate Pharmacy students of NIPER, Mohali. Study duration 
was six months period of time (Nov. 2014 to Apr. 2015). Participants who were willing 
to participate in the study were included. Participants who had not completed or 
did not return back the questionnaire were excluded. Data collection was based on 
pre-designed questionnaire containing close ended questions. Participants were 
assured of their confidentiality and anonymity. Data collected was analysed using 
€ 750, € 1000 and € 5000 was 0.721, 0.724, 0.730, 0.733, 0.737 and 0.789. conclusions: 
Based on the evidence presented, SPRM/CDSS is likely to be determined to be cost-
effective in comparison with usual pharmaceutical care.
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oBjectives: Menopausal symptoms associated with reduction in the levels of oestro-
gen can be alleviated through the use of pharmacotherapy. A systematic review and 
meta-analysis were conducted to compare the relative efficacy/safety of conjugated 
oestrogens (CE) 0.45mg/bazedoxifene (BZA) 20mg with other available treatments for 
management of postmenopausal symptoms (PMS). MethoDs: MEDLINE, EMBASE 
and Cochrane databases were systematically searched (December 2014) to identify 
randomised controlled trials evaluating CE/BZA, tibolone, oestradiol (E2)/(micronised) 
progestin combinations and placebo in this indication. Eligible trials included women 
with an intact uterus and at least 12 months since last menses. Vasomotor symptoms 
(VMS, number of “moderate/severe” hot flushes [HF]) at 4 weeks and the rate of uterine 
bleeding (UB) were analysed via Bayesian network meta-analysis (NMA) with results 
presented as weighted mean difference (WMD) and hazard ratios (HR), respectively, 
along with 95% credible intervals (Crls). A direct pairwise meta-analysis was con-
ducted on the number of “moderate/severe” HF at 12 weeks and severity at 4 and 12 
weeks, expressed as WMD and 95% confidence intervals (CIs). Data were validated by 
Abacus International. results: Twenty-two studies met the inclusion criteria for the 
meta-analysis. CE/BZA significantly lowered the daily number of “moderate/severe” 
HF compared with placebo at both 4 weeks (WMD:-3.10 [95% CrI:-4.34, -1.88]) and 12 
weeks (WMD:-3.21 [95% CI:-4.30, -2.12; p< 0.05]). The HF severity score was significantly 
lower in patients treated with CE/BZA versus placebo at both 4 weeks (WMD:-0.39 
[95% CI:-0.58, -0.20]; p< 0.05) and 12 weeks (WMD:-0.66 [95% CI:-0.89, -0.44]; p< 0.001). 
The rate of UB with CE/BZA was not significantly different versus placebo (HR: 0.81 
[95% CrI: 0.30, 2.20]) and was significantly less than tibolone 2.5mg (HR: 0.28 [95% CrI: 
0.08, 0.93]). conclusions: CE/BZA demonstrates a favourable risk-benefit profile 
for management of PMS. CE/BZA treated patients reported a significant improvement 
in VMS with no increased risk of UB versus placebo.
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oBjectives: Students of higher education institutions are prone to practices 
of substance abuse and risky sexual behavior due to individual, peer, social and 
ecological influences. The objective of the current study is to assess practices of 
substance abuse and its relationship with risky sexual behavior among ASTU 
Students. MethoDs: A total of 447 respondents were selected to fill the question-
ers by using stratified, systematic and random sampling from undergraduate regular 
students while only 426 (95.3%) were completed the questioner correctly and the 
analyses of results were based on 426 respondents. Informal interview with five 
key respondents were also conducted for triangulation of results. The results were 
analyzed by using descriptive statistics such as frequencies and percentage, and 
inferential statistics such as chi-square (x2) and binary logistic regression. results: 
Prevalence of substance abuse increases with gender differences (X2(6.315) = .012, 
P< .05); previous place of residence (X2(18.327) = .000, P< .05) and school attended 
before joining the university (X2(8.807) = .003, P< .05); while decreases with current 
place of residence (c2(.152) = .696, P> .05). However, sexual behavior of respondents 
decreases with gender difference (X2(.155) = .694, P> .05); previous place of residence 
(X2(.122) = .727, P> .05); school attended before joining the university (X2(.092) = 
.762, P> .05); and current place of residence (X2(.088)= .767, P> .05). conclusions: 
There is statistical significant relation between substance abuse and gender dif-
ferentials, previous places of residences and school attended before joining the 
university while there is no statistical relation between current places of residences. 
Therefore prevention of practices of substance abuse and risky sexual behaviors 
among students should be strengthened at primary and secondary school program.
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oBjectives: Older patients represent those at greatest risk of adverse drug reac-
tions (ADR) and potentially inappropriate prescribing (PIP). Therefore, they also 
represent the greatest opportunity for pharmacotherapy optimisation. Examining 
prescribing patterns is a key step towards identifying areas in which prescribing 
can be improved. MethoDs: As part of the SENATOR project, prescribing data was 
collected on 464 older patients presenting at emergency departments with acute 
illness at sites across six EU countries. Patients were followed up at discharge and 
three months post-discharge, where possible. The prescribing data was analysed 
to compare prescribing across the six countries. As the STOPP/START screening 
tool organises criteria by physiological system, the prescribed medicines were 
classified accordingly. results: In total 8666 medicines were recorded for the 
464 patients. The overall percentages were as follows; cardiovascular indications 
39.01% (n= 3381), central nervous system indications 7.69% (n= 666), endocrine 
disorders 6.91% (n= 599), gastrointestinal indications 9.04% (n= 783), musculo-
skeletal indications 4.3% (n= 373), respiratory tract indications 11.97% (n= 1037), 
urogenital indications 2.05% (n= 178), no valid indication recorded 3.80% (n= 329), 
